Ajanta Pharma Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2025, declared Interim Dividend of 28 per equity share.
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ajanta Pharma's board declared a 1st interim dividend of Rs. 28 per share (face value Rs. 2), totaling about Rs. 349.82 crores, with November 10, 2025 as the record date and payment from November 20, 2025. For Q2 FY26, consolidated revenue rose 14% YoY to Rs. 1,354 cr, EBITDA grew 5% to Rs. 328 cr, and profit after tax jumped 20% to Rs. 260 cr. The company had a Rs. 41 cr mark-to-market forex loss; excluding this, EBITDA grew 9% to Rs. 369 cr with a 27% margin. The US Generic segment surged 48% YoY, India branded generics grew 12%, and ROCE stood at a healthy 30%. H1 FY26 revenue was Rs. 2,656 cr (up 14%) with PAT at Rs. 516 cr (up 12%).
The strong double-digit profit growth and sizable dividend payout signal healthy cash generation and shareholder-friendly capital allocation. US business momentum is a clear positive, though the forex loss and an August 2025 income tax search are minor watchpoints. The stock may see short-term support from the dividend announcement.